October 2026 — NephCure celebrates another landmark milestone for the rare kidney disease (RKD) community following the U.S. Food and Drug Administration’s (FDA) accelerated approval of ULTOMIRIS® (ravulizumab-cwvz) as the first and only C5 ... Read more The post The FDA Grants Accelerated Approval of ULTOMIRIS (ravulizumab-cwvz) for Adults with IgA Nephropathy appeared first on NephCure .
https://nephcure.org/the-fda-grants-accelerated-approval-of-ultomiris-ravulizumab-cwvz-for-adults-with-iga-nephropathy/